<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02497040</url>
  </required_header>
  <id_info>
    <org_study_id>uludagu</org_study_id>
    <nct_id>NCT02497040</nct_id>
  </id_info>
  <brief_title>The Effects of Scalp Block With Bupivacaine Versus Levobupivacaine</brief_title>
  <official_title>Effects of Scalp Block With Bupivacaine Versus Levobupivacaine on Haemodynamic Response to Head Pinning and Efficacy on Postoperative Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uludag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uludag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ninety American Society of Anesthesiologists (ASA) Physical Status classification system I-II
      patients were recruited for a randomised, placebo-controlled, double-blind study and were
      randomly divided into three groups to receive either 20 ml of 0.5% bupivacaine (Group B;
      n=30), 20 ml of 0.5% levobupivacaine (Group L; n=30) or saline as a placebo (Group C; n=30).
      Scalp block was performed 5 min before head pinning. The primary outcome of the study was
      mean arterial pressure (MAP) and secondary outcomes were heart rate (HR), visual analogue
      scale (VAS) scores, additional intraoperative and postoperative drug use. Postoperative pain
      was evaluated using a 10-cm visual analogue scale (VAS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following approval from the Research Ethics Committee of the Medical Faculty of UludaÄŸ
      University, (the date and protocol number assigned by this ethics committee were March 4,
      2008 and 5/30, respectively),written informed consent was obtained from patients undergoing
      elective scheduled operations involving craniotomy during anaesthesia consultations. Ninety
      American Society of Anesthesiologists (ASA) Physical Status classification system I or II
      patients of either sex between 18-85 years of age were allocated to this randomised,
      prospective, placebo-controlled, double-blind study. The patients were randomly divided into
      three groups using a sealed-enveloped technique to receive either 20 ml of 0.5% bupivacaine
      (Group B (n=30)), 20 ml of 0.5% levobupivacaine (Group L (n=30)) or saline as a placebo
      (Group C (n=30)). Twenty-millilitre syringes for the block were prepared and numbered by a
      blinded assistant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Arterial Pressure</measure>
    <time_frame>220+-70 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>bupivacaine,levobupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 ml of 0.5% bupivacaine 20 ml of 0.5% levobupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>levobupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 ml of 0.5% levobupivacaine saline as a placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 ml of 0.5% bupivacaine saline as a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine</intervention_name>
    <description>local injection</description>
    <arm_group_label>bupivacaine,levobupivacaine</arm_group_label>
    <arm_group_label>levobupivacaine</arm_group_label>
    <other_name>chirocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>local injection</description>
    <arm_group_label>bupivacaine,levobupivacaine</arm_group_label>
    <arm_group_label>bupivacaine</arm_group_label>
    <other_name>marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>local injection</description>
    <arm_group_label>levobupivacaine</arm_group_label>
    <arm_group_label>bupivacaine</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists (ASA) Physical Status classification system 1-2

        Exclusion Criteria:

          -  Uncontrolled hypertension, arrhythmia, diabetes mellitus or coagulopathy, coronary
             artery disease or a proven or suspected allergy to bupivacaine or levobupivacaine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hulya bilgin</last_name>
    <role>Study Director</role>
    <affiliation>uludag university anaesthesia and reanimation department</affiliation>
  </overall_official>
  <reference>
    <citation>Pinosky ML, Fishman RL, Reeves ST, Harvey SC, Patel S, Palesch Y, Dorman BH. The effect of bupivacaine skull block on the hemodynamic response to craniotomy. Anesth Analg. 1996 Dec;83(6):1256-61.</citation>
    <PMID>8942596</PMID>
  </reference>
  <reference>
    <citation>Agarwal A, Sinha PK, Pandey CM, Gaur A, Pandey CK, Kaushik S. Effect of a subanesthetic dose of intravenous ketamine and/or local anesthetic infiltration on hemodynamic responses to skull-pin placement: a prospective, placebo-controlled, randomized, double-blind study. J Neurosurg Anesthesiol. 2001 Jul;13(3):189-94.</citation>
    <PMID>11426091</PMID>
  </reference>
  <reference>
    <citation>Costello TG, Cormack JR, Mather LE, LaFerlita B, Murphy MA, Harris K. Plasma levobupivacaine concentrations following scalp block in patients undergoing awake craniotomy. Br J Anaesth. 2005 Jun;94(6):848-51. Epub 2005 Apr 7.</citation>
    <PMID>15817709</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2015</study_first_submitted>
  <study_first_submitted_qc>July 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <results_first_submitted>May 15, 2016</results_first_submitted>
  <results_first_submitted_qc>December 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2018</results_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uludag University</investigator_affiliation>
    <investigator_full_name>banu otlar can</investigator_full_name>
    <investigator_title>anesthesia and reanimation</investigator_title>
  </responsible_party>
  <keyword>anaesthesia</keyword>
  <keyword>local anaesthesia</keyword>
  <keyword>hemodynamics</keyword>
  <keyword>bupivacaine</keyword>
  <keyword>levobupivacaine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bupivacaine,Levobupivacaine</title>
          <description>20 ml of 0.5% bupivacaine 20 ml of 0.5% levobupivacaine
Levobupivacaine: local injection
Bupivacaine: local injection</description>
        </group>
        <group group_id="P2">
          <title>Levobupivacaine</title>
          <description>20 ml of 0.5% levobupivacaine saline as a placebo
Levobupivacaine: local injection
placebo: local injection</description>
        </group>
        <group group_id="P3">
          <title>Bupivacaine</title>
          <description>20 ml of 0.5% levobupivacaine saline as a placebo
Bupivacaine: local injection
placebo: local injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bupivacaine,Levobupivacaine</title>
          <description>20 ml of 0.5% bupivacaine 20 ml of 0.5% levobupivacaine
Levobupivacaine: local injection
Bupivacaine: local injection</description>
        </group>
        <group group_id="B2">
          <title>Levobupivacaine</title>
          <description>20 ml of 0.5% levobupivacaine saline as a placebo
Levobupivacaine: local injection
placebo: local injection</description>
        </group>
        <group group_id="B3">
          <title>Bupivacaine</title>
          <description>20 ml of 0.5% levobupivacaine saline as a placebo
Bupivacaine: local injection
placebo: local injection</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Arterial Pressure</title>
        <time_frame>220+-70 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine,Levobupivacaine</title>
            <description>20 ml of 0.5% bupivacaine 20 ml of 0.5% levobupivacaine
Levobupivacaine: local injection
Bupivacaine: local injection</description>
          </group>
          <group group_id="O2">
            <title>Levobupivacaine</title>
            <description>20 ml of 0.5% levobupivacaine saline as a placebo
Levobupivacaine: local injection
placebo: local injection</description>
          </group>
          <group group_id="O3">
            <title>Bupivacaine</title>
            <description>20 ml of 0.5% levobupivacaine saline as a placebo
Bupivacaine: local injection
placebo: local injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Arterial Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110" spread="20"/>
                    <measurement group_id="O2" value="105" spread="20"/>
                    <measurement group_id="O3" value="100" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bupivacaine,Levobupivacaine</title>
          <description>20 ml of 0.5% bupivacaine 20 ml of 0.5% levobupivacaine
Levobupivacaine: local injection
Bupivacaine: local injection</description>
        </group>
        <group group_id="E2">
          <title>Levobupivacaine</title>
          <description>20 ml of 0.5% levobupivacaine saline as a placebo
Levobupivacaine: local injection
placebo: local injection</description>
        </group>
        <group group_id="E3">
          <title>Bupivacaine</title>
          <description>20 ml of 0.5% levobupivacaine saline as a placebo
Bupivacaine: local injection
placebo: local injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>nause, vomitting,hypertensÄ±on</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Banu Otlar Can</name_or_title>
      <organization>uludag university</organization>
      <phone>+905323827044</phone>
      <email>botlar@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

